COVER2PROTECT PTE LTD

Founded: 2017
HEALTHCARE / REMOTE MONITORING, WELLNESS
5-10 employees
Stage: Prototype/ MVP
Singapore based technology platform for people with special needs around healthcare. (my)aiBUD is an AI-driven preventive healthcare solution which is aiming towards decreasing the cost of healthcare by early detection and intervention. Our advanced wearable is able to track the following parameters: ECG, PWG, Heart Rate, Blood Pressure, and daily activity. Our platform is open and can integrate with other wearables or health devices via Bluetooth. We have built our machine learning models to train our AI engine (my)aiBUD to understand and learn various medical vitals in conjugation with various structured and unstructured data around the health of a person. We also have built a full digital ecosystem surrounding the medical needs of a patient to help him get healthcare FASTER, BETTER and CHEAPER. These ecosystem providers constitute of Hospitals, Labs, Pharmacies, Ambulances and Wellness experts
Projects Created
(my)aiBUD
AI Driven Predictive and Connected Health Platform
0
MedStartr
Index Score
Leverage advanced wearables and AI to track and interpret vitals enabling preventive healthcare. Develop a platform which connects the healthcare ecosystem of doctors, ambulances, ...
Singapore, Singapore
$ 250,000 goal
  • 7 Likes
  • Partner
  • Mentor
  • This campaign has ended but you can still get involved.
Company Contacts
Address:

31 WHITEWATER PASIR RIS STREET 72

Singapore, 02

SG 518769

Website URL:
Contact Us:
9185 8601
Connect With Us
Contact Person
Team Members
Fix QuickBooks Technical Issues with the Help of Experts

Important Disclosure: MedStartr.com is a website owned and operated by MedStartr, Inc., which is not a broker-dealer, funding portal or investment advisor; and neither the website nor MedStartr, Inc. participate in the offer or sale of securities. All securities related activity is conducted through Young America Capital, LLC, a registered broker-dealer and member of FINRA/SIPC. No communication, through this website, email or in any other medium, should be construed as a recommendation for any securities offering.